TO WHAT LEVEL WE MUST DECREASE SYSTOLIC BLOOD PRESSURE IN HYPERTENSIVE PATIENTS NOT SUFFERING FROM TYPE 2 DIABETES MELLITUS?


Cite item

Full Text

Abstract

The article is concerned with the feasibility of the maximum possible decrease of systolic blood pressure in hypertensive patients without type 2 diabetes mellitus. In particular, the results of the Cardio-Sis study are discussed.

References

  1. London G., Guerin A. Influence of arterial pulse and reflective waves on systolic blood pressure and cardiac function. J. Hypertens. 1999; 17 (Suppl. 2): S3-S6.
  2. O'Rourke M.F. Isolated systolic hypertension, pulse pressure, and arterial stiffness as risk factors for cardiovascular disease. Curr. Hypertens. Rep. 1999; 1: 204-211.
  3. Beltran A., McVeigh G., Morgan D. et al. Arterial compliance abnormalities in isolated systolic hypertension. Am. J. Hypertens. 2001; 14:1007-1011.
  4. Российское Медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008.
  5. Kannel W.B. Prevalence and implications of uncontrolled systolic hypertension. Drugs Aging. 2003; 20: 277-286.
  6. Stampler J., Stampler R., Neaton J. Blood pressure, systolic and diastolic, and cardiovascular risks. Arch. Intern. Med. 1993; 153: 598-615.
  7. Broda G. Isolated systolic hypertension is a strong predictor of cardiovascular and all-cause mortality in the middle-aged population: Warsaw Pol-MONICA Follow up Project. J. Clin. Hypertens. (Greenwich). 2000; 2: 305-311.
  8. Qureshi A.I., Suri M.F., Mohammad Y., et al. Isolated and borderline isolated systolic hypertension relative to long-term risk and type of stroke: a 20-year follow-up of the national health and nutrition survey. Stroke 2002; 33: 2781-2788.
  9. Hozawa A., Ohkubo T., Nagai K. et al. Prognosis of isolated systolic and isolated diastolic hypertension as assessed by self-measurement of blood pressure at home: the Ohasama study. Arch. Intern. Med. 2000; 160: 3301-3306.
  10. Gerber L.M., Shmukler C., Alderman M.H. Differences in urinary albumin excretion rate between normotensive and hypertensive, white and nonwhite subjects. Arch. Intern. Med. 1992; 152: 373-377.
  11. Young J.H., Klag M.J., Muntner P. et al. Blood pressure and decline in kidney function: findings from the Systolic Hypertension in the Elderly Program (SHEP). J. Am. Soc. Nephrol. 2002; 13: 2776-2782.
  12. Domrongkitchaiporn S., Sritara P., Kitiyakara C. et al. Risk factors for development of decreased kidney function in a southeast Asian population: a 12-year cohort study. J. Am. Soc. Nephrol. 2005; 16: 791-799.
  13. Cicconetti P., Morelli S., Ottaviani L. et al. Blunted nocturnal fall in blood pressure and left ventricular mass in elderly individuals with recently diagnosed isolated systolic hypertension. Am. J. Hypertens. 2003; 16 (11 Pt. 1): 900-905.
  14. Pini R., Cavallini M.C., Bencini F. Cardiac and vascular remodeling in older adults with borderline isolated systolic hypertension: the ICARe Dicomano Study. Hypertension 2001; 38: 1372-1376.
  15. Kark M., Karnehed N., Rasmussen F. Blood pressure in young adulthood and later disability pension. A population-based study on 867 672 men from Sweden. Blood Press. 2007;16(6): 362-366.
  16. Cirillo M., Stellato D., Laurenzi M. et al Pulse pressure and isolated systolic hypertension: association with microalbuminuria. The GUBBIO Study Collaborative Research Group. Kidney Int. 2000; 58: 1211-1218.
  17. Bog-Hansen E., Lindblad U., Ranstam J. et al. Impaired glucose metabolism and obesity in Swedish patients with borderline isolated systolic hypertension: Skaraborg Hypertension and Diabetes Project. Diabetes. Obes. Metab. 2001; 3: 25-31.
  18. Os I., Gudmundsdottir H., Kjeldsen S.E., Oparil S. Treatment of isolated systolic hypertension in diabetes mellitus type 2. Diabetes Obes. Metab. 2006; 8(4): 381-387.
  19. Оганов Р.Г., Лепахин В.К., Фитилев С.Б. и др. Качество профилактики и лечения сердечно-сосудистых заболеваний и их осложнений у больных сахарным диабетом 2 типа в амбулаторных условиях. Кардиоваскулярная терапия и профилактика 2008; 7(7): 9-14.
  20. UK Prospective Diabetes Study (UKPDS) Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. Br. Med. J. 1998; 317: 705-713.
  21. Holman R.R., Paul S.K., Bethel M.A. et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N. Engl. J. Med. 2008; 359(15): 1565-1576.
  22. ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide on microvascular and macrovascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomized controlled trial. Lancet 2007; 370: 829-840.
  23. Alam M.G., Barri Y.M. Systolic blood pressure is the main etiology for poorly controlled hypertension. Am. J. Hypertens. 2003; 16:140-143.
  24. Wong N.D., Lopez V.A., L'Italien G. et al. Inadequate control of hypertension in US adults with cardiovascular disease comorbidities in 2003-2004. Arch. Intern. Med. 2007; 167(22): 2431-2436.
  25. SHEP Cooperative Research Study Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. J.A.M.A. 1991; 265: 3255-3264
  26. Staessen J.A., Fagard R., Thijs L. et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet 1997; 350: 757-764.
  27. Staessen J.A., Gasowski J., Wang J.G. et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865-872.
  28. Staessen J.A., Wang J. Do ancillary properties of antihypertensive drugs explain the outcome results of recent trials? J. Nephrol. 2002; 15(4): 422-427.
  29. Applegate W.B., Byington R.P. MIDAS, the Multicenter Isradipine/Diuretic Atherosclerosis Study. Design features and baseline data. Am. J. Hypertens. 1991; 4 (2 Pt. 2): 114S-117S.
  30. Borhani N.O., Mercuri M., Borhani P.A. et al. Final outcome results of the Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS). A randomized controlled trial. JAMA. 1996; 276(10): 785-791.
  31. Teo K.K., Burton J.R., Buller C.E. et al. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation. 2000; 102: 1748-1754.
  32. Sleight P., Redon J., Verdecchia P. et al. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J. Hypertens. 2009; 27(7): 1360-1369.
  33. Verdecchia P., Staessen J.A., Angeli F. et al.; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009; 374: 525-533.
  34. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии: просто о сложном. Consilium medicum. 2006; 8(5): 5-11.
  35. Hansson L., Zanchetti A., Carruthers S.G. et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998; 351: 1755-1762.
  36. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). J.A.M.A. 2002; 288: 2981-2997.
  37. Alam S., Purdie D.M., Johnson A.G. Evaluation of the potential interaction between NaCl and prostaglandin inhibition in elderly individuals with isolated systolic hypertension. J. Hypertens. 1999; 17: 1195-1202.
  38. Фомин В.В. Можно ли обойтись без гидрохлоротиазида в лечении артериальной гипертензии? Клиническая нефрология. 2009; 3: 62-67.
  39. Staessen J.A., Wang J.G., Thijs L. Cardiovascular prevention and blood pressure reduction: a quantitative overview updated until 1 March 2003. J. Hypertens. 2003; 21(6): 1055-1076.
  40. Chrysant S.G., Neutel J.M., Ferdinand K.C.; INCLUSIVE investigators. Irbesartan/hydrochlorothiazide for the treatment of isolated systolic hypertension: a subgroup analysis of the INCLUSIVE trial. J. Natl. Med. Assoc. 2009; 101(4): 300-307.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies